Botox Injection, Powder, Lyophilized, For Solution
Product Images NDC 0023-1145

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Botox (NDC 0023-1145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Botox 01

An anatomical illustration showing the interior of the bladder with labeled features including the dome, bladder base, trigone, opening of the left ureter, and marked injection sites. Close-up views depict the positioning of an injection needle at the bladder dome and near the bladder base, demonstrating sites for intradermal or intramuscular injection.*

FDA Label Image

Botox 02

An anatomical diagram showing injection sites for BOTOX (onabotulinumtoxinA) around the head and neck. Four views illustrate labeled points for injecting Corrugator, Procerus, Frontalis muscles on the forehead; Temporalis at the side of the head; Occipitalis muscles at the back of the head; and Cervical paraspinal and Trapezius muscles on the neck, each with specified unit doses.*

FDA Label Image

Botox 03

An anatomical illustration showing muscles of the forearm and hand. It labels various muscles including brachialis, brachioradialis, flexor carpi ulnaris, flexor carpi radialis, flexor digitorum sublimis and profundus, opponens pollicis, flexor pollicis brevis and longus, adductor pollicis, lumbricals/interossei, pronator teres, and pronator quadratus.*

FDA Label Image

Botox 04

An anatomical illustration showing the posterior lower leg muscles with labeled injection sites. Muscles depicted include the medial head of the gastrocnemius, lateral head of the gastrocnemius, soleus, tibialis posterior, and the flexor digitorum longus with flexor hallucis longus. The image highlights specific targeted areas on these muscles.*

FDA Label Image

Botox 05

An anatomical diagram of the human forearm muscles showing injection points for botulinum toxin treatment. The labeled muscles include Biceps brachii, Brachialis, Brachioradialis, Flexor carpi radialis, Flexor digitorum sublimis (superficialis), Flexor carpi ulnaris, and Flexor digitorum profundus. The illustration highlights specific muscle groups relevant for intramuscular or intradermal injection sites.*

FDA Label Image

Botox 06

An anatomical illustration showing four views of calf muscles targeted for injection: medial head of gastrocnemius, lateral head of gastrocnemius, soleus, and tibialis posterior. Each muscle is highlighted with dots marking specific injection points relevant to BOTOX (onabotulinumtoxinA) use.*

FDA Label Image

Botox 07

A cross-sectional illustration of a clustered structure composed of multiple round cells or units, arranged in a roughly circular pattern. The drawing is schematic, likely representing a biological or anatomical grouping, with each cell outlined and shaded to show separation.*

FDA Label Image

Botox 08

This line graph shows the mean change from baseline in episodes per day over 12 weeks post-treatment comparing Placebo and BOTOX 100 U. The x-axis represents weeks post-treatment (0, 2, 6, 12 weeks), and the y-axis represents the mean change in episodes per day with error bars. BOTOX 100 U shows a significant decrease in episodes at week 12 compared to Placebo.*

FDA Label Image

Botox 09

Line graph depicting mean change from baseline in episodes per day over 12 weeks post-treatment comparing BOTOX 100 U injection versus placebo. The graph shows a significant reduction in episodes for the BOTOX group compared to placebo, with data points at weeks 0, 2, 6, and 12 and associated standard error bars.*

FDA Label Image

Botox 0a

A line graph showing mean change in episodes per week from baseline with standard error bars over 12 weeks post-treatment. It compares placebo (dotted line) and BOTOX 200 U (solid line), demonstrating a statistically significant reduction at 6 weeks for BOTOX versus placebo.*

FDA Label Image

Botox 0b

A line graph showing the mean change in episodes per week from baseline over 12 weeks post-treatment comparing placebo and BOTOX 200 U. The BOTOX group shows a larger decrease in episodes with statistically significant difference at week 6 (P < 0.05). Error bars represent standard error.*

FDA Label Image

Botox 0c

A line graph comparing mean change in headache days from baseline over 24 weeks for BOTOX versus placebo. The x-axis shows visits at weeks 4, 8, 12, 16, 20, and 24. The y-axis shows headache days' mean change with standard error. BOTOX shows a greater reduction in headache days than placebo at multiple time points, with statistically significant differences indicated.*

FDA Label Image

Botox 0d

A line graph showing mean change from baseline in headache days over 24 weeks, comparing placebo and BOTOX treatments. The x-axis represents visit weeks (4, 8, 12, 16, 20, 24), and the y-axis shows the mean change in headache days with standard error bars. BOTOX shows a greater reduction in headache days compared to placebo, with statistical significance indicated at several time points.*

FDA Label Image

Botox 0e

Line graph showing mean MAS change from baseline over time for BOTOX (onabotulinumtoxinA) versus placebo. The x-axis represents visits from week 2 to week 12, and the y-axis shows mean changes with error bars. BOTOX shows greater reduction at weeks 4 and 6 compared to placebo, with statistical significance indicated.*

FDA Label Image

Botox 0f

A line graph comparing mean CGI scores over time from Week 2 to Week 12 for treatment with BOTOX and placebo. The graph shows higher scores for BOTOX from Week 2 through Week 8, with statistically significant differences at multiple visits, followed by a convergence of scores by Week 12. The graph includes error bars representing standard error.*

FDA Label Image

Botox 10

A line graph comparing mean MAS change from baseline over 12 weeks among three groups: BOTOX 6 U/kg, BOTOX 3 U/kg, and placebo. The x-axis shows visit weeks 2, 4, 6, 8, and 12. The y-axis measures the mean MAS change with standard error bars. Both BOTOX treatment groups show a greater reduction from baseline compared to placebo.*

FDA Label Image

Botox 11

A line graph showing the mean Clinical Global Impression (CGI) Score with standard error bars over 12 weeks, comparing three treatments: BOTOX 6 U/kg, BOTOX 3 U/kg, and placebo. The x-axis marks visits from week 2 to week 12, and the y-axis shows the mean CGI score ranging approximately from 0.0 to 2.0. BOTOX treatments show higher mean scores than placebo.*

FDA Label Image

Botox 12

A line graph depicting mean MAS change from baseline over time by visit week for three groups: BOTOX 8 U/inc, BOTOX 4 U/inc, and Placebo. The y-axis shows mean change from baseline with standard error, and the x-axis represents visits at weeks 2, 4, 6, 8, and 12. The data reflect treatment effects on MAS change across these time points.*

FDA Label Image

Botox 13

A line graph showing mean CGI scores with standard error bars over visits from Week 2 to Week 12. Three groups are compared: BOTOX 8 U/kg, BOTOX 4 U/kg, and placebo. Scores for both BOTOX groups remain higher than placebo throughout the timeline, with slight variations over the weeks.*

FDA Label Image

Botox 14

FDA Label Image

Botox 15

FDA Label Image

Botox 16

The packaging label for BOTOX injection, containing onabotulinumtoxinA at 100 Units per vial. The label indicates it is a lyophilized powder for injection, suitable for intradermal or intramuscular use, distributed by Allergan, Inc. The design features dosage strength, usage instructions, storage conditions, and a barcode on a predominantly white background with purple and orange accents.*

FDA Label Image

Botox 17

BOTOX 200 Units/vial injection lyophilized powder for solution with onabotulinumtoxinA by Allergan, Inc. The packaging highlights 200 Units/vial strength, usage for intramuscular, intradetrmal, or intra-articular injection, storage instructions at 2°-8°C, and includes barcode and lot/expiration date area. It is a single-dose vial with preservative-free formulation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.